SAT-044 Treatment of Hypogonadal Men with a New Oral Testosterone Undecanoate (TU) Formulation Improves Psychosexual, Well-Being and Body Composition and Bone Density Parameters

Introduction and Objective: A new, first-in-class oral testosterone (T) replacement therapy product [T-undecanoate (TU) capsules] was recently approved by FDA to treat hypogonadal men. Clinical trials were conducted to evaluate, in part, the impact of oral TU therapy on important secondary efficacy...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Endocr Soc
Hlavní autoři: Swerdloff, Ronald S, Amory, John K, Dobs, Adrian S, Wang, Christina, Danoff, Theodore M, Dudley, Robert E
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2020
Témata:
Reproductive Endocrinology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7368366/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.1297
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky